1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Amneal Adds Xolair Rival To Biosimilars Pipeline

Kashiv Biosciences-Developed Omalizumab Becomes Eighth Product In Amneal’s Roster

 
• By Dave Wallace

Amneal has revealed the latest addition to its biosimilars pipeline, in the form of an omalizumab rival to Xolair developed by Kashiv Biosciences.

Red pipes on white background
Amneal is adding to its biosimilars pipeline • Source: Shutterstock

Amneal Pharmaceuticals is adding a biosimilar rival to Xolair (omalizumab) to its biosimilars pipeline, with the Kashiv Biosciences-developed product becoming the eighth biosimilar in the firm’s portfolio.

With three biosimilars already on the market in the US – Alymsys (bevacizumab-maly), Fylnetra (pegfilgrastim-pbbk), and Releuko (filgrastim-ayow) – Amneal also has denosumab rivals to Prolia and Xgeva in its pipeline, courtesy of a recent partnership with mAbxience. (Also see "Amneal And mAbxience Ally On Denosumab In US" - Generics Bulletin, 13 October, 2023.) Meanwhile, the company also has on-body injector and pre-filled autoinjector versions of pegfilgrastim in development

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.